Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators. Cohen M, et al. Among authors: brassat d. JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240. JAMA Neurol. 2014. PMID: 24566807 Clinical Trial.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups. Barbin L, et al. Among authors: brassat d. Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29. Neurology. 2016. PMID: 26826205 Free PMC article.
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks. Pignolet B, et al. Among authors: brassat d. Neurology. 2016 Dec 6;87(23):2491-2494. doi: 10.1212/WNL.0000000000003401. Epub 2016 Nov 4. Neurology. 2016. PMID: 27815407 Clinical Trial. No abstract available.
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network. Fissolo N, et al. Among authors: brassat d. Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22. Ann Neurol. 2017. PMID: 28681388 Clinical Trial.
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups. Laplaud DA, et al. Among authors: brassat d. Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12. Neurology. 2019. PMID: 31300547 Free PMC article.
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators. Vukusic S, et al. Among authors: brassat d. JAMA Neurol. 2020 Jan 1;77(1):94-102. doi: 10.1001/jamaneurol.2019.2670. JAMA Neurol. 2020. PMID: 31479149 Free PMC article.
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C. Cohen M, et al. Among authors: brassat d. Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30. Mult Scler. 2021. PMID: 33124504
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, deSèze J, Labauge P, Vukusic S, Papeix C, Martinez-Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Bourre B, Defer G, Montalban X, Brassat D, Comabella M. Fissolo N, et al. Among authors: brassat d. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 26;8(4):e1003. doi: 10.1212/NXI.0000000000001003. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33903203 Free PMC article. Clinical Trial.
Cancer and multiple sclerosis in the era of disease-modifying treatments.
Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M. Lebrun C, et al. Among authors: brassat d. J Neurol. 2011 Jul;258(7):1304-11. doi: 10.1007/s00415-011-5929-9. Epub 2011 Feb 4. J Neurol. 2011. PMID: 21293872
Neuromyelitis optica in France: a multicenter study of 125 patients.
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J. Collongues N, et al. Among authors: brassat d. Neurology. 2010 Mar 2;74(9):736-42. doi: 10.1212/WNL.0b013e3181d31e35. Neurology. 2010. PMID: 20194912
153 results